Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - isotretinoin -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: disodium edetate; purified water; yellow beeswax; indigo carmine; butylated hydroxyanisole; brilliant scarlet 4r; dl-alpha-tocopherol; gelatin; soya oil; partially hydrogenated soya oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); titanium dioxide; hydrogenated vegetable oil - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects asssociated with its use. isotretinoin should be reversed for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; dl-alpha-tocopherol; disodium edetate; butylated hydroxyanisole; partially hydrogenated soya oil; yellow beeswax; hydrogenated vegetable oil; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); brilliant scarlet 4r; iron oxide black; titanium dioxide; purified water - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: purified water; titanium dioxide; dl-alpha-tocopherol; sorbitol solution (70 per cent) (non-crystallising); yellow beeswax; butylated hydroxyanisole; soya oil; partially hydrogenated soya oil; sunset yellow fcf; glycerol; disodium edetate; hydrogenated soya oil; gelatin - dermatane is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: gelatin; dl-alpha-tocopherol; soya oil; titanium dioxide; purified water; yellow beeswax; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxyanisole; partially hydrogenated soya oil; hydrogenated vegetable oil; disodium edetate; glycerol - dermatane is indicated for the treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 5 mg - capsule, soft - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); glycerol; purified water; butylated hydroxyanisole; hydrogenated vegetable oil; titanium dioxide; disodium edetate; soya oil; dl-alpha-tocopherol; gelatin; yellow beeswax; partially hydrogenated soya oil - treatment of patients with severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 40 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; sorbitol solution (70 per cent) (non-crystallising); hydrogenated soya oil; dl-alpha-tocopherol; soya oil; disodium edetate; butylated hydroxyanisole; sunset yellow fcf; gelatin; partially hydrogenated soya oil; yellow beeswax; purified water - oratane is indicated for the treatment of severe cystic acne and a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cyctic acne who are unresponsive to conventional therapy, including systemic antibiotics.